Back

Benefit of LDL-C lowering with evolocumab on cardiovascular outcomes by age & sex: an analysis of the FOURIER trial

28 August 2018 (09:06 - 09:24)
Organised by:
Congress Presentation Part of: PCSK9 inhibitors - For the many or the few? Lipid-Lowering Agents ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Peter S Sever

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
PCSK9 Inhibitors - State of the art
Professor J. Armitage (Oxford, GB)
Slides Video
Presentation thumbnail
PCSK9-Inhibitor treatment of cardiovascular high risk patients in a real-world setting
Doctor U. Kassner (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Inhibition of PCSK9 reduces infarct size and arrhythmia susceptibility in cardiac ischeamia/reperfusion injury through attenuating mitochondrial dysfunction and increasing connexin43 phosphorylation
Doctor T. Priyadechawarawong (Chiang Mai, TH)
Abstract Slides Video
Presentation thumbnail
Future hurdles in PCSK9 - Inhibition.
Professor E. Stein (Cincinnati, US)
Slides Video

Access the full session

Session thumbnail
PCSK9 inhibitors - For the many or the few?

The Event

Event poster

ESC Congress 2018

28 August 2018 09:06 CET
You may be interested in
thumbnail
Congress Presentation
Where are we now? Decision-making in LDL-C lowering and CV risk
thumbnail
Webinar
Unmet needs in lipid management: treatment goals and how to achieve them
thumbnail
Congress Presentation
2025 Focused Update of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources